Cargando…

IMMUNOREACTANTS IN RHEUMATOID SYNOVIAL EFFUSIONS

Measurements were made of the IgG in synovial fluid which is synthesized by the intact rheumatoid synovium. In five rheumatoid subjects 12–24% of the IgG present in their synovial fluid was derived from local production. No evidence for local production was found in patients with degenerative arthri...

Descripción completa

Detalles Bibliográficos
Autor principal: Zvaifler, Nathan J.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1971
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2139080/
https://www.ncbi.nlm.nih.gov/pubmed/19867372
_version_ 1782143712965427200
author Zvaifler, Nathan J.
author_facet Zvaifler, Nathan J.
author_sort Zvaifler, Nathan J.
collection PubMed
description Measurements were made of the IgG in synovial fluid which is synthesized by the intact rheumatoid synovium. In five rheumatoid subjects 12–24% of the IgG present in their synovial fluid was derived from local production. No evidence for local production was found in patients with degenerative arthritis or Reiter's syndrome. It was estimated that as much as 95 mg of IgG was produced by the synovium of a single knee joint daily. Rheumatoid inflammation is associated with the presence of large numbers of white blood cells, predominantly polymorphonuclear, in the articular cavity. Each day as many as one billion white cells enter the articular cavity to participate in this inflammatory response. Factors causing the directed migration of polymorphonuclear leukocytes were found in the majority of rheumatoid effusions studied. The chemotactic activity is, in large part, related to the fifth (C5) and sixth (C6) components of human complement. Physical-chemical techniques indicate that the activity is attributable to C 567 and C5a, a cleavage product of C5. In addition to the presence of preformed chemotactic factors, more than half of the rheumatoid fluids contain an enzyme capable of generating chemotactic activity from the fifth component (C5) of human complement. This information supports the concept that rheumatoid joint inflammation is an example of immune complex disease in which a significant proportion of the immunoreactants are derived from local production.
format Text
id pubmed-2139080
institution National Center for Biotechnology Information
language English
publishDate 1971
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21390802008-04-17 IMMUNOREACTANTS IN RHEUMATOID SYNOVIAL EFFUSIONS Zvaifler, Nathan J. J Exp Med Rheumatoid Arthritis and Other Diseases Measurements were made of the IgG in synovial fluid which is synthesized by the intact rheumatoid synovium. In five rheumatoid subjects 12–24% of the IgG present in their synovial fluid was derived from local production. No evidence for local production was found in patients with degenerative arthritis or Reiter's syndrome. It was estimated that as much as 95 mg of IgG was produced by the synovium of a single knee joint daily. Rheumatoid inflammation is associated with the presence of large numbers of white blood cells, predominantly polymorphonuclear, in the articular cavity. Each day as many as one billion white cells enter the articular cavity to participate in this inflammatory response. Factors causing the directed migration of polymorphonuclear leukocytes were found in the majority of rheumatoid effusions studied. The chemotactic activity is, in large part, related to the fifth (C5) and sixth (C6) components of human complement. Physical-chemical techniques indicate that the activity is attributable to C 567 and C5a, a cleavage product of C5. In addition to the presence of preformed chemotactic factors, more than half of the rheumatoid fluids contain an enzyme capable of generating chemotactic activity from the fifth component (C5) of human complement. This information supports the concept that rheumatoid joint inflammation is an example of immune complex disease in which a significant proportion of the immunoreactants are derived from local production. The Rockefeller University Press 1971-09-01 /pmc/articles/PMC2139080/ /pubmed/19867372 Text en Copyright © 1971 by The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Rheumatoid Arthritis and Other Diseases
Zvaifler, Nathan J.
IMMUNOREACTANTS IN RHEUMATOID SYNOVIAL EFFUSIONS
title IMMUNOREACTANTS IN RHEUMATOID SYNOVIAL EFFUSIONS
title_full IMMUNOREACTANTS IN RHEUMATOID SYNOVIAL EFFUSIONS
title_fullStr IMMUNOREACTANTS IN RHEUMATOID SYNOVIAL EFFUSIONS
title_full_unstemmed IMMUNOREACTANTS IN RHEUMATOID SYNOVIAL EFFUSIONS
title_short IMMUNOREACTANTS IN RHEUMATOID SYNOVIAL EFFUSIONS
title_sort immunoreactants in rheumatoid synovial effusions
topic Rheumatoid Arthritis and Other Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2139080/
https://www.ncbi.nlm.nih.gov/pubmed/19867372
work_keys_str_mv AT zvaiflernathanj immunoreactantsinrheumatoidsynovialeffusions